John Lawson
Cardiovascular Disease · Grapevine, TXNPI 1386674935
Payments from drug & device makers
Across 128 payments — averaging $26.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$473
- Novartis$431
- Amgen$383
- E.r. Squibb & Sons, L.L.C.$270
- Astellas Pharma US Inc$245
- Pfizer$225
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,362100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 4 | $473 |
| Novartis | 17 | $431 |
| Amgen | 17 | $383 |
| E.r. Squibb & Sons, L.L.C. | 13 | $270 |
| Astellas Pharma US Inc | 13 | $245 |
| Pfizer | 8 | $225 |
| Sanofi-aventis U.S. LLC | 12 | $188 |
| Bayer | 3 | $170 |
| AstraZeneca | 5 | $165 |
| Novo Nordisk | 3 | $160 |
| Johnson & Johnson | 11 | $158 |
| Cvrx, Inc. | 1 | $112 |
| Regeneron Healthcare Solutions, Inc. | 5 | $98 |
| Boehringer Ingelheim | 3 | $58 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $47 |
| Amarin Pharma, Inc. | 2 | $40 |
| Heartflow, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Gilead | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| G Medical Diagnostic Services, Inc. | 1 | $14 |
| Cardinal Health 200 LLC | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Confirm Rx$451
- Repatha$125
- CAMZYOS$125
- VYNDAQEL$121
- Ozempic$117
- Barostim Neo System$112
How this compares
$3,369 in reported general payments places this provider in the 45th percentile of 1,515 cardiovascular disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 31 | $37,690 |
| EntrestoSacubitril/Valsartan | 19 | $25,881 |
| XareltoRivaroxaban | 14 | $13,260 |
| Metoprolol Succinate | 45 | $563 |
| Ezetimibe | 12 | $281 |
| Atorvastatin Calcium | 23 | $258 |
| ClopidogrelClopidogrel Bisulfate | 24 | $239 |
| Olmesartan Medoxomil | 12 | $237 |
| Losartan Potassium | 24 | $233 |
| Amlodipine Besylate | 22 | $187 |
| Carvedilol | 23 | $164 |
| Lisinopril | 19 | $164 |
| Hydrochlorothiazide | 17 | $145 |
| Rosuvastatin Calcium | 18 | $128 |
| Metoprolol Tartrate | 21 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $225 | $37,69031 claims |
| NovartisEntresto | $431 | $25,88119 claims |
| Johnson & JohnsonXarelto | $158 | $13,26014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Grapevine
- John OsborneGrapevine$1.3M
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.